SMARCA4 and non-small cell lung carcinoma: A retrospective series of 352 surgical NSCLC found that patients harboring mutations in TP53, STK11 or SMARCA4 had a worse overall survival (OS) after adjustment for confounding factors, with a hazard ratio (HR) for all causes of mortality respectively at 1.47 (95%CI 1.02–2.13), 1.66 (95%CI 1.05–2.61) and 2.1 (95%CI 1.22–3.61) [42].